Tendie Bot

Tendie.bot

Login
MRNA Articles
reddit/

Moderna's Historic Cancer Vaccine Win Sends MRNA Surging 70% – Reddit Goes Wild

Moderna and Merck announced a successful Phase 3 trial for a personalized mRNA melanoma vaccine, the first in history. MRNA surged 70% premarket, and Reddit communities from r/wallstreetbets to r/ValueInvesting erupted with options plays, scalping strategies, and discussions of the wider mRNA platform potential.

  1. Moderna and Merck announced a successful Phase 3 trial for a personalized mRNA melanoma vaccine, the first of its kind.

  2. MRNA stock surged 70% in premarket, with Reddit discussion exploding across r/wallstreetbets and r/stocks.

  3. The win validates mRNA technology beyond COVID, opening a new growth avenue for Moderna.

On August 19, 2026,

MRNA
$MRNA and
MRK
$MRK made history by announcing positive Phase 3 trial results for their personalized mRNA-based cancer vaccine targeting melanoma. The combination therapy, paired with Keytruda, significantly reduced cancer recurrence and spread in high-risk melanoma patients. The news sent
MRNA
$MRNA shares soaring 70% in premarket trading, with
MRK
$MRK also rising 10%.

Reddit Erupts: Options, Scalping, and the Next Play

The r/wallstreetbets community was electric. One user posted a long

MRNA
$MRNA $60C position that had gained 449%, turning $16,857 into over $75,000. Another trader described scalping the stock, buying dips near $135 and selling around $163, pocketing $4,000 despite regret at selling early. Meanwhile, a doctor on the subreddit highlighted a potential 'piggyback play' in genetic sequencing companies like
PSNL
$PSNL, arguing that personalized cancer vaccines will drive massive demand for tumor sequencing.

MRNA

Beyond the Hype: What the Trial Means

On r/stocks, the landmark trial result was described as 'truly groundbreaking' and 'the first time this has ever happened.' The r/ValueInvesting subreddit noted that Moderna's market cap nearly tripled overnight, expressing surprise at the lack of broader discussion on the valuation shift. While the data is still pending full publication and overall survival results, the market's reaction reflects the immense potential of mRNA technology beyond infectious diseases. For

MRNA
$MRNA, this win provides a critical new growth pipeline after the collapse of COVID-19 revenue.

Subscribe to Tendie.bot for more market recaps.